Epigenetic Therapies And Technologies: World Market Prospects 2013-2023
Leading companies and market valueOverall world revenue for epigenetic applications will reach $2,518m in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.
In our study you find discussions of these organisations and many others:• Celgene• Eisai• Merck & Co.• Roche• Astex Pharmaceuticals• Exact Sciences• Orion Genomics.
This decade, many opportunities will arise. Our work shows you the technological and commercial possibilities.
Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps youTo sum up, our investigation gives you the following knowledge on the topic: • Forecasted revenues to 2023 for the overall world market and 3 submarkets - you discover prospects for the industry's future • Predicted revenues of 6 products to 2023 - you find prospects for drugs, both existing brands and those awaiting launch • Market forecasting to 2023 for US, Canada, Japan, Germany, France, UK, Spain, Italy, BRIC nations and Europe - you see national and regional outlooks • Assessments of companies - you find activities, products, strategies and outlooks • Review of R&D by technology and disease - you hear about progress in established and emerging research areas • Opinions on the sector - you read our interviews with leaders in that industry • Competition and opportunities influencing sales - you see what affects the future • Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints • Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success. You gain information found nowhere else That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative. With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV